Abstracts Archive - Page 402 of 2425 - ACR Meeting Abstracts

Abstract Number: 1975 • ACR Convergence 2022
Identifying MicroRNAs Associated with Neuropathic Pain in Patients with Rheumatoid Arthritis (RA)
Lissette Delgado-Cruzata¹, Milena Rodriguez Alvarez², Veronika Zenkeviciute³, Nickolas Almodovar³ and Toni-Ann Bravo³, ¹City University of New York, New York, NY, ²SUNY Downstate Medical Center, New York, NY, ³John Jay College, CUNY, New York, NY
Background/Purpose: Neuropathic pain is one of the most common clinical characteristics of rheumatoid arthritis (RA). It often does not subside with the use of DMARD,…
Abstract Number: 1973 • ACR Convergence 2022
Association Between Activity Limitations, Sleep Disturbance, Pain Sensitivity, Pain Intensity, and Widespread Pain in Adults with Rheumatoid Arthritis
Burcu Aydemir¹, Jing Song², Lutfiyya Muhammad³, Daniela Grimaldi¹, Kathryn Reid¹, Phyllis Zee¹, Rowland Chang⁴ and Yvonne Lee¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Evanston, IL, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Despite treatment with strong immunosuppressive medications, more than half of patients with rheumatoid arthritis (RA) still report pain. Pain can spread from joint sites…
Abstract Number: 1966 • ACR Convergence 2022
Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Eva van Geel¹, Bafrin Abdulmajid¹, Annelies Blanken² and Michael Nurmohamed³, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: Controlling inflammation with tumour necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients is hypothesized to reduce their cardiovascular risk. Arterial wall thickness (carotid…
Abstract Number: 1979 • ACR Convergence 2022
Tc99m Tilmanocept Imaging Can Differentiate the Fibroid Pathotype of Rheumatoid Arthritis from Non-Fibroid Pathotypes in Patients
Costantino Pitzalis¹, rebecca hands², Swamy Venuturupalli³, Ami Ben-artzi⁴, Eric Ruderman⁵, Harris Perlman⁶, Arthur Mandelin⁵, Mara Leach⁷, Addison Hasselbach⁷, Bonnie Abbruzzese⁷, Rachael Hershey⁷, Beth Potter⁷, Jessica Fitzpatrick⁷, Aaron Thornton⁷, Michael Blue⁷, Jonathan Graf⁸, David Ralph⁷ and Michael Rosol⁷, ¹Queen Mary University of London, London, United Kingdom, ²William Harvey Research Institute, London, United Kingdom, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University, Chicago, IL, ⁷Navidea Biopharmaceuticals, Dublin, OH, ⁸Ucsf, San Francisco, CA
Background/Purpose: The primary objective of this study is to assess the relationship between joint-specific Tc99m tilmanocept (TIL) uptake values and the pathobiology of RA-involved joint…
Abstract Number: 1978 • ACR Convergence 2022
Using Administrative Health Data to Construct a Frailty Index as a Measure of Susceptibility to Adverse Health Outcomes Among Individuals with Rheumatoid Arthritis
Alexandra Legge¹ and Diane Lacaille², ¹Arthritis Research Canada, Dalhousie University, Halifax, NS, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Frailty is increasingly recognized among individuals living with RA. While several tools are available to assess frailty in clinical settings, it is less readily…
Abstract Number: 1788 • ACR Convergence 2022
Pulmonary Vascular Dysfunction Occurs in Association with Hyperuricaemia: Assessment by a Novel Non-Invasive Measurement of Pulmonary Pulse Wave Transit Time
Rachael Flood¹, Nicole Fagan², Diarmuid O'Brien¹, Colm Kirby¹, David Kane¹ and Ronan Mullan¹, ¹Tallaght University Hospital, Dublin, Ireland, ²St James' Hospital, Dublin, Ireland
Background/Purpose: Hyperuricaemia is common in pulmonary hypertension (PH) occurring in up to 80% of patients with serum uric acid levels(sUA) correlating with poor PH outcomes.…
Abstract Number: 1968 • ACR Convergence 2022
Dysregulation of γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis
Klára Prajzlerová¹, Olga Kryštůfková², Nora Petrovská², Petra Hánová¹, Hana Hulejová¹, Jiří Vencovský², Ladislav Šenolt² and Mária Filková², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Non-conventional T cells (γδ-T and NK-T cells) and natural killer (NK) cells are involved in the regulation of the immune system, and their alteration…
Abstract Number: 1967 • ACR Convergence 2022
Sex Differences in Employment Outcomes in Patients with Recent Onset Rheumatoid Arthritis
Carol Hitchon¹, Marie-France Valois², orit schieir², Louis Bessette³, Gilles Boire⁴, Susan Bartlett⁵, Glen Hazlewood⁶, Edward Keystone⁷, Janet Pope⁸, Carter Thorne⁹, Diane Tin¹⁰ and Vivian Bykerk¹¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²McGill University, Montréal, QC, Canada, ³Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰The Arthritis Program Research Group, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY
Background/Purpose: Early work cessation and reduced work and activity productivity are significant contributors to the personal and societal costs associated with rheumatoid arthritis (RA). We…
Abstract Number: 1691 • ACR Convergence 2022
Pentagalloyl Glucose Inhibits MSU-Induced Inflammation via Transforming Growth Factor-β-Activated Kinase 1 (TAK1)
Paul Panipinto, Anil Singh, Farheen Sultan Shaikh and Salahuddin Ahmed, Washington State University, Spokane, WA
Background/Purpose: Gout disease flares occur when primed macrophages interact with and phagocytose monosodium urate crystals (MSU), activating IL-1β via the NLRP3 inflammasome. Abrogation of inflammasome…
Abstract Number: 1748 • ACR Convergence 2022
Deep Immune Profiling of Cytotoxic T Cells (CTL) from Patients with Ankylosing Spondylitis Revealed a Subset of CTL Co-Expressing PD-1 and TIGIT That Resists Immune Exhaustion
Michael Tang¹, Addison Pacheco², Zoya Qaiyum³, Melissa Lim¹ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Unresolved, chronic inflammation is a key feature of Ankylosing Spondylitis (AS) yet the immunological events perpetuating remain unclear. The strongest genetic association with AS…
Abstract Number: 1965 • ACR Convergence 2022
Autoantibodies Against a Specific 25-mer Peptide from P. Gingivalis Are Present in Sera of Patients with Rheumatoid Arthritis and Early Arthritis
Hsin-Yi Peng¹, Ting-Yin Xue¹, Fei-Hung Hsieh¹, Yi-Ko Chen¹, Mei-Chin Yin², Che-Yi Chao², Shu-Yao Tsai², Chung-Ping Lin³, Po-Hao Huang³, Chien-Chung Huang³, Jiunn-Horng Chen³, Chung-Ming Huang³, Der-Yuan Chen⁴, Joung-Liang Lan⁵ and Gregory Tsay³, ¹China Medical University, Taichung, Taiwan, ²Asia University, Taichung, Taiwan, ³China Medical University Hospital, Taichung, Taiwan, ⁴China Medical University Hospital Rheumatology and Immunology Center, Taichung, Taiwan, ⁵China Medoical University Hospital, Taichung, Taiwan
Background/Purpose: The presence of rheumatoid factor (RF) or anti-cyclic citrullinated protein/peptide antibodies (ACPA) are included in the 2010 the ACR/EULAR classification criteria of rheumatoid arthritis…
Abstract Number: 1977 • ACR Convergence 2022
Tc99m Tilmanocept Imaging Predicts Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy
Jonathan Graf¹, Martin Jacobs², Debbie Gladd-Foley³, Yelliann Ruiz-Irizarry⁴, Alan Kivitz⁵, Melvin Churchill⁶, Arash Kardan⁷, Mara Leach⁸, David Ralph⁸, Nicole Korczak⁸, Addison Hasselbach⁸, Bonnie Abbruzzese⁸, Rachael Hershey⁸, Beth Potter⁸, Jessica Fitzpatrick⁸, Aaron Thornton⁸, Michael Blue⁸ and Michael Rosol⁸, ¹Ucsf, San Francisco, CA, ²Kettering Network Radiologists, Kettering, OH, ³Premier Rheumatology of Oklahoma, Tulsa, OK, ⁴Jackson Health System, Innovation Medical Research Center, Palmetto Bay, FL, ⁵Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁶Arthritis Center of Nebraska, Bryan Health, Lincoln, NE, ⁷Baylor College of Medicine, Department of Radiology, Houston, TX, ⁸Navidea Biopharmaceuticals, Dublin, OH
Background/Purpose: Effective and expeditious control of rheumatoid arthritis (RA) disease activity using a treat-to-target (T2T) strategy is crucial to prevent long term damage and disability.…
Abstract Number: 1756 • ACR Convergence 2022
Adverse Events in Patients with Inflammatory Joint Diseases: Results from the EULAR Coronavirus Vaccine (COVAX) Physician-reported Registry
Ana Lúcia Martins Fernandes¹, Jose A Gomez-Puerta², Juan Camilo Sarmiento-Monroy², Saskia Lawson-Tovey³, Kimme Hyrich⁴, Laure Gossec⁵, Loreto Carmona⁶, Anja Strangfeld⁷, Elsa Mateus⁸, Ana Maria Rodrigues⁹, Eric Hachulla¹⁰, Marta Mosca¹¹, Patrick Durez¹², Bernd Raffeiner¹³, Nicolas Roux¹⁴, Viellard Eric¹⁵, Olivier Brocq¹⁶, Julija Zepa¹⁷, Inita Bulina¹⁸, Eva Strakova¹⁹, Vanda Mlynarikova²⁰, Emoke Šteňová²¹, Martin Soubrier²², Xavier Mariette²³ and Pedro Machado²⁴, ¹Centro Hospitalar Universitário do Algarve, Faro, Portugal, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴The University of Manchester, Manchester, United Kingdom, ⁵Sorbonne Université, Paris, France, ⁶Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁷Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁸EULAR, Lisboa, Portugal, ⁹Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, ¹⁰University of Lille, LILLE, France, ¹¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹²Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ¹³Department of Rheumatology, Central Hospital of Bolzano, Bolzano, Italy, ¹⁴Service de Rhumatologie, Hôpital Robert Schuman, Metz, France, ¹⁵Private practice, St. Malo, France, ¹⁶Rheumatology- CH Princesse Grace, Monaco, Monaco, ¹⁷Riga Stradins University, Latvia, Pauls Stradins Clinical University Hospital, Centre of Rheumatology, Riga, Latvia, Riga, Latvia, ¹⁸Center of Rheumatology, Paul Stradins Clinical University hospital, Riga, Latvia, Riga, Latvia, ¹⁹Department of Internal Medicine, Faculty Hospital Prešov, Presov, Slovakia, ²⁰National Institute of Rheumatic Diseases, Piešťany, Slovakia, ²¹University Hospital, Bratislava, Slovakia, ²²Gabriel-Montpied Hospital, Clermont-Ferrand, France, ²³Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ²⁴University College London, London, United Kingdom
Background/Purpose: Patients with inflammatory/autoimmune rheumatic and musculoskeletal diseases (I-RMDs) were excluded from SARS-CoV-2 vaccination development programs. Therefore, concerns regarding the safety and effectiveness of SARS-CoV-2…
Abstract Number: 1694 • ACR Convergence 2022
Skin Exposure to UV Light Triggers Podocyte and Distal Tubular Injury, in the Presence of CD177+ Neutrophil Cell Cluster
Angelique Cortez¹, Lindsay Mendyka¹, Fred Kolling² and Sladjana Skopelja-Gardner¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: Sensitivity to ultraviolet (UV) light affects ~ 80% of systemic lupus erythematosus (SLE) patients. UV light exposure of lupus skin leads to local and…
Abstract Number: 1589 • ACR Convergence 2022
Multiple Switching Between the Biosimilar Adalimumab PF-06410293 (Abrilada™) and Reference Adalimumab (Humira®)in Combination with Methotrexate in Patients with Moderately to Severely Active Rheumatoid Arthritis
Roy Fleischmann¹, Sharad Lakhanpal², WASSIM Saikali³, Daniel Alvarez⁴, Donna S Cox⁴, Claudia Ianos⁵, Karen Wang⁶ and Wuyan Zhang⁷, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³Rheumatology and Pulmonary Clinic, Beckley, WV, ⁴Pfizer, Inc, Collegeville, PA, ⁵Pfizer Zürich, Zürich, Switzerland, ⁶Pfizer, Inc, La Jolla, CA, ⁷Pfizer, Inc, Lake Forest, IL
Background/Purpose: PF-06410293 (ADL-afzb) is an adalimumab (ADL) biosimilar approved in the US, the EU, and 19 other countries. Biosimilarity of ADL-afzb with reference ADL (ADL-REF)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].